Evidence map›Paper›PMID 34227241›Full record

ArticleThoracic cancer2021

Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab.

Yoshiko Mizushina, Fumiyoshi Ohyanagi, Jun Shiihara, Motoko Nomura, Hiromitsu Ohta, Hisashi Oshiro, Hiroyoshi Tsubochi, Gen Kusaka, Yasuhiro Yamaguchi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yoshiko MizushinaDivision of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.ORCID 0000-0002-9988-5755
Fumiyoshi OhyanagiDivision of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Jun ShiiharaDivision of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Motoko NomuraDivision of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Hiromitsu OhtaDivision of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Hisashi OshiroDepartment of Pathology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Hiroyoshi TsubochiDivision of Thoracic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.ORCID 0000-0002-2174-9454
Gen KusakaDepartment of Neurosurgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Yasuhiro YamaguchiDivision of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.ORCID 0000-0002-6899-4406
Jichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 52-year-old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death-ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase fusion gene. However, brain metastasis and chest wall tumor relapse occurred. Considering insufficient improvement with gamma knife treatment for brain metastasis and combination chemotherapy (paclitaxel, carboplatin, and bevacizumab), pembrolizumab monotherapy and palliative irradiation therapy for chest metastases were started after brain tumor volume reduction using craniotomy. Brain edema and chest wall metastases markedly improved following a pseudoprogression of the brain edema accompanied by a performance status decline; this effect continued until 11 cycles of pembrolizumab administration.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBrain NeoplasmsCarcinomaHumansLung NeoplasmsMaleMiddle AgedPneumonectomyThoracic NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 Antigenpembrolizumabimmune checkpoint inhibitorlung cancerpembrolizumabpseudoprogressionspindle cell carcinoma

Identifiers

PMID34227241
PMCPMC8364993
OpenAlexW3178758616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.